Deniz, currently serving as currently serving as Chief Medical Officer, Global Head of Medical & Pharmacovigilance at GE Healthcare Lifesciences, played a key role in the filing and approval of multiple drugs and in-vivo diagnostics agents in several therapeutic areas of unmet need, including omalizumab for the treatment of asthma in the US and the EU.
